DSGN
NASDAQDesign Therapeutics Inc.
Price$10.44+0.11 (+1.06%)
01:30 PM07:45 PM
News · 26 weeks29+20%
2025-12-072026-05-31
Mix1990d
- SEC Filings9(47%)
- Other4(21%)
- Analyst2(11%)
- Insider2(11%)
- Earnings2(11%)
Latest news
25 items- PRDesign Therapeutics to Participate in 2026 Jefferies Global Healthcare ConferenceCARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class
- SECSEC Form 8-K filed by Design Therapeutics Inc.8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- PRDesign Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich AtaxiaDT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing DT-216P2 generally well-tolerated Data support advancement toward registrational development Management to host conference call and webcast today at 8:00 am ET CARLSBAD, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced positive biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (FA). DT-216P
- PRDesign Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage bi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.SCHEDULE 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
- ANALYSTCantor Fitzgerald initiated coverage on Design TherapeuticsCantor Fitzgerald initiated coverage of Design Therapeutics with a rating of Overweight
- SECSEC Form 10-Q filed by Design Therapeutics Inc.10-Q - Design Therapeutics, Inc. (0001807120) (Filer)
- SECDesign Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- PRDesign Therapeutics Announces First Quarter 2026 Financial Results and Recent Business UpdatesAdditional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of $222.8 Million at Quarter-End Provide Runway to Support Ongoing Clinical Execution CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported first quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio. "The first quarter was marked by continued operational execu
- SECSEC Form DEFA14A filed by Design Therapeutics Inc.DEFA14A - Design Therapeutics, Inc. (0001807120) (Filer)
- SECSEC Form DEF 14A filed by Design Therapeutics Inc.DEF 14A - Design Therapeutics, Inc. (0001807120) (Filer)
- INSIDERSEC Form 4 filed by Shapiro David4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shapiro David3 - Design Therapeutics, Inc. (0001807120) (Issuer)
- SECDesign Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- ANALYSTJefferies initiated coverage on Design Therapeutics with a new price targetJefferies initiated coverage of Design Therapeutics with a rating of Buy and set a new price target of $15.00
- SECSEC Form S-8 filed by Design Therapeutics Inc.S-8 - Design Therapeutics, Inc. (0001807120) (Filer)
- SECSEC Form 10-K filed by Design Therapeutics Inc.10-K - Design Therapeutics, Inc. (0001807120) (Filer)
- SECDesign Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- PRDesign Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business UpdatesTrials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported fourth quarter and full year 2025 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio. "The fourth quarter capped a year of strong execution and meaningful progress across our GeneTAC® portfolio," said Pratik Sha
- PRDesign Therapeutics to Participate in Upcoming Investor ConferencesCARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 1:20 p.m. ET (virtual)Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 2:20 p.m. ET in Miami, FL Live webcasts of each presentation will be available here and in the investors section of the company's website at www.designtx.com.The webcasts will be archived for at least 30 days fo
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.SCHEDULE 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
- SECSEC Form 8-K filed by Design Therapeutics Inc.8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- ANALYSTOppenheimer initiated coverage on Design Therapeutics with a new price targetOppenheimer initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $18.00
- INSIDERSEC Form 4 filed by Chief Medical Officer Storgard Chris4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Jeffries Sean4 - Design Therapeutics, Inc. (0001807120) (Issuer)
DSGN FAQ
7 questionsWhat does Design Therapeutics Inc. do?
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.Where does DSGN stock trade?
Design Therapeutics Inc. (DSGN) is listed on NASDAQ.What sector and industry is DSGN in?
Design Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Design Therapeutics Inc. go public?
Design Therapeutics Inc. (DSGN) completed its IPO in 2021.What are analysts saying about DSGN?
Design Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-05-12. Recent price targets range from $600.00 to $1800.00.What companies are similar to DSGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DSGN side-by-side with any of them on Quantisnow.How can I track DSGN on Quantisnow?
Quantisnow aggregates Design Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DSGN to receive live email and push alerts on every new disclosure.